Sugi Predict

Sugi Predict / Compounds / SCHEMBL578602

SCHEMBL578602

SCHEMBL578602

Brc1ccc(CC2CCNCC2)cc1

nearest known ligand 0.67

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ GBA1 P04062 1/20 0.66
▸ SLC6A4 P31645 6/20 0.51
▸ KDM1A O60341 1/20 0.42
▸ EP300 Q09472 1/20 0.42
▸ FPR3 P25089 1/20 0.41
▸ FPR2 P25090 1/20 0.41
▸ SLC6A2 P23975 2/20 0.41
▸ HRH3 Q9Y5N1 2/20 0.41
▸ HRH4 Q9H3N8 1/20 0.41
▸ PRMT5 O14744 1/20 0.38
▸ WDR77 Q9BQA1 1/20 0.38
▸ CHRM2 P08172 1/20 0.38
▸ CCR5 P51681 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6923742 0.90 GBA1 (0.54) GBA1SLC6A4KDM1AEP300SLC6A2
SCHEMBL29890511 0.89 GBA1 (0.52) GBA1SLC6A4KDM1AEP300FPR3
SCHEMBL1994019 0.89 GBA1 (0.52) GBA1SLC6A4KDM1AEP300FPR3
SCHEMBL1994022 0.89 GBA1 (0.52) GBA1SLC6A4KDM1AEP300FPR3
Hydrochloric Acid SCHEMBL26187178 0.87 GBA1 (0.50) GBA1SLC6A4KDM1AEP300FPR3
SCHEMBL1119520 0.85 SLC6A2 (0.46) GBA1SLC6A4SLC6A2
Ammonia Solution, Strong SCHEMBL987776 0.83 SLC6A2 (0.45) GBA1SLC6A4SLC6A2CHRM2CCR5
Tert-Butyl Formate SCHEMBL27891735 0.82 GBA1 (0.46) GBA1SLC6A4KDM1AEP300FPR3
SCHEMBL23574239 0.81 SLC6A2 (0.44) GBA1SLC6A4SLC6A2HRH3
SCHEMBL6770189 0.81 KMT2A (0.46) GBA1SLC6A4SLC6A2HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12378224-B2 Heteroaryl compounds and their use as Mer inhibitors DONG-A SOCIO HOLDINGS CO., LTD. (KR) 2025-08-05 — — US disclosed
US-20240246909-A1 EBNA1 Inhibitors and Methods Using Same WISTAR INST (US) 2024-07-25 — — US disclosed
US-11912659-B2 EBNA1 inhibitors and methods using same THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2024-02-27 — — US disclosed
US-20220064112-A1 EBNA1 Inhibitors and Methods Using Same WISTAR INST (US) 2022-03-03 — — US disclosed
EP-3523292-B1 HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS DONG A SOCIO HOLDINGS CO LTD (KR) 2021-12-15 — — EP disclosed
US-20210371398-A1 HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS DONG A SOCIO HOLDINGS CO LTD (KR) 2021-12-02 — — US disclosed
CN-113149885-A EBNA1 inhibitors and methods of using the same 威斯塔解剖学和生物学研究所 2021-07-23 — — CN disclosed
EP-3294705-B1 EBNA1 INHIBITORS AND METHODS USING SAME WISTAR INST (US) 2021-07-21 — — EP disclosed
US-10981867-B2 EBNA1 inhibitors and methods using same THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2021-04-20 — — US disclosed
CN-107848964-B EBNA1 inhibitors and methods of using the same 威斯塔解剖学和生物学研究所 2021-03-19 — — CN disclosed
WO-2010115279-A1 KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME UNIVERSITY HEALTH NETWORK (CA) 2010-10-14 — — WO disclosed
WO-2009151598-A1 DIAZACARBAZOLES AND METHODS OF USE GENENTECH, INC. (US) 2009-12-17 — — WO disclosed
CN-100497345-C 2, 3-dihydro-6-nitroimidazolo [2,1-b] oxazole compounds for the treatment of tuberculosis OTSUKA PHARMA CO LTD (JP) 2009-06-10 — — CN disclosed
US-7196199-B2 Antiserotonine agents; antidepressants MITSUBISHI PHARMA CORPORATION (JP) 2007-03-27 — — US disclosed
CN-1878777-A 2,3-dihydro-6-nitroimidazo (2,1-b) oxazole compounds for the treatment of tuberculosis OTSUKA PHARMA CO LTD (JP) 2006-12-13 — — CN disclosed
EP-1188747-B1 PHENOXYPROPYLAMINE COMPOUNDS MITSUBISHI PHARMA CORP (JP) 2005-09-07 — — EP disclosed
US-20040138227-A1 Phenoxypropylamine compounds NISHIYAMA AKIRA 2004-07-15 — — US disclosed
US-6720320-B2 ANTISEROTONINE AGENTS MITSUBISHI PHARMA CORPORATION (JP) 2004-04-13 — — US disclosed
US-20020111358-A1 Phenoxypropylamine compounds MITSUBISHI PHARMA CORPORATION (JP) 2002-08-15 — — US disclosed
EP-1188747-A1 PHENOXYPROPYLAMINE COMPOUNDS Mitsubishi Pharma Corporation (JP) 2002-03-20 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138227-A1 Phenoxypropylamine compounds HTR1A, HTR1D, HTR5A GBA1 4268/4885SLC6A4 10/4885KDM1A 226/4885
US-12378224-B2 Heteroaryl compounds and their use as Mer inhibitors MERTK, RET, ERBB2 GBA1 1968/4885SLC6A4 1162/4885KDM1A 2923/4885
US-20210371398-A1 HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS MERTK, RET, ERBB2 GBA1 1968/4885SLC6A4 1162/4885KDM1A 2923/4885
US-10981867-B2 EBNA1 inhibitors and methods using same MLLT1, EBNA1BP2, MALT1 GBA1 868/4885SLC6A4 4709/4885KDM1A 48/4885
US-20240246909-A1 EBNA1 Inhibitors and Methods Using Same MLLT1, EBNA1BP2, MALT1 GBA1 868/4885SLC6A4 4709/4885KDM1A 48/4885
US-20020111358-A1 Phenoxypropylamine compounds HTR1A, HTR1D, HTR5A GBA1 4268/4885SLC6A4 10/4885KDM1A 226/4885
US-20220064112-A1 EBNA1 Inhibitors and Methods Using Same MLLT1, EBNA1BP2, MALT1 GBA1 868/4885SLC6A4 4709/4885KDM1A 48/4885
US-11912659-B2 EBNA1 inhibitors and methods using same MLLT1, EBNA1BP2, MALT1 GBA1 868/4885SLC6A4 4709/4885KDM1A 48/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.